We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
US biotechnology company Bioverativ has entered a new research collaboration with UK-based Bicycle Therapeutics to discover, develop and commercialise new therapies for haemophilia and sickle cell disease.